Amended Current Report Filing (8-k/a)
February 11 2019 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
July 19,
2017
CYBRDI, INC.
(Name
of Small Business Issuer in its Charter)
California
|
95-2461404
|
(State or Jurisdiction of Incorporation or
|
(I.R.S. Employer Identification No.)
|
Organization)
|
|
29 Changan South Road, Yanta District
Xian
City, Shaanxi Province, China 710061
(Address of principal
executive offices)
+86 029-88103388
(Telephone Number of
Principal Executive Offices)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
EXPLANATORY NOTE
This Current Report on Form 8-K/A amends and restates the
Current Report on Form 8-K filed with the Securities and Exchange Commission on
February 8, 2019. Specifically, Item1.01 has been reproduced in this Amendment
with information to clarify the described transaction.
Item 1.01
|
Entry into a Material Definitive
Agreement
|
On July 19, 2017, Cybrdi. Inc. (the Company) entered into a
share transfer agreement (the Agreement) with Xian Alena Biotechnology Co.,
Ltd (the Purchaser). Neither the Company nor its affiliates have any material
relationship with the Purchaser other than with respect to the Agreement.
Pursuant to the Agreement, the Company agreed to sell its 80%
equity interest in Shaanxi Chaoying Biotechnology Co., Ltd for a consideration
of 25.6 million RMB (approximately $3.8 million). The closing for the sale of
the shares occurred in October 2017.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 11, 2019
|
CYBRDI, INC.
|
|
|
|
|
By:
|
/s/
Yanbiao Bai
|
|
|
Name: Yanbiao Bai
|
|
|
Title: Chief Executive Officer
|